CN114828960A - 治疗儿童个体的cln2病的方法 - Google Patents
治疗儿童个体的cln2病的方法 Download PDFInfo
- Publication number
- CN114828960A CN114828960A CN202080068971.3A CN202080068971A CN114828960A CN 114828960 A CN114828960 A CN 114828960A CN 202080068971 A CN202080068971 A CN 202080068971A CN 114828960 A CN114828960 A CN 114828960A
- Authority
- CN
- China
- Prior art keywords
- individual
- cln2
- patients
- study
- rhtpp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893535P | 2019-08-29 | 2019-08-29 | |
| US62/893,535 | 2019-08-29 | ||
| PCT/US2020/048704 WO2021042020A1 (en) | 2019-08-29 | 2020-08-31 | Methods for treating cln2 disease in pediatric subjects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114828960A true CN114828960A (zh) | 2022-07-29 |
Family
ID=72470612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080068971.3A Pending CN114828960A (zh) | 2019-08-29 | 2020-08-31 | 治疗儿童个体的cln2病的方法 |
Country Status (24)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12303693B2 (en) * | 2021-04-02 | 2025-05-20 | Neuropace, Inc. | Systems and methods for controlling operation of an implanted neurostimulation system based on a mapping of episode durations and seizure probability biomarkers |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103096918A (zh) * | 2010-06-25 | 2013-05-08 | 夏尔人类遗传性治疗公司 | 治疗试剂的cns 递送 |
| CN107847615A (zh) * | 2015-05-08 | 2018-03-27 | 生物马林药物股份有限公司 | 用于治疗cln2疾病的tpp1调配物及方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6302685B1 (en) | 1997-09-16 | 2001-10-16 | University Of Medicine And Dentistry Of New Jersey | Human lysosomal protein and methods of its use |
| US20020006400A1 (en) | 2000-05-11 | 2002-01-17 | Peter Lobel | Recombinant human CLN2 protein and methods of its production and use |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| AU2016341428B2 (en) * | 2015-10-23 | 2021-12-02 | University Of Iowa Research Foundation | Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection |
| KR20260086827A (ko) * | 2018-11-14 | 2026-06-10 | 리젠엑스바이오 인크. | 신경원성 세로이드 리포푸신증에 대한 유전자 요법 |
-
2020
- 2020-08-31 EP EP24177169.0A patent/EP4438120A3/en active Pending
- 2020-08-31 LT LTEPPCT/US2020/048704T patent/LT4021575T/lt unknown
- 2020-08-31 CN CN202080068971.3A patent/CN114828960A/zh active Pending
- 2020-08-31 KR KR1020227010387A patent/KR20220054375A/ko active Pending
- 2020-08-31 EP EP20771408.0A patent/EP4021575B1/en active Active
- 2020-08-31 US US17/638,029 patent/US20220273775A1/en active Pending
- 2020-08-31 HR HRP20240871TT patent/HRP20240871T1/hr unknown
- 2020-08-31 WO PCT/US2020/048704 patent/WO2021042020A1/en not_active Ceased
- 2020-08-31 FI FIEP20771408.0T patent/FI4021575T3/fi active
- 2020-08-31 MX MX2022002451A patent/MX2022002451A/es unknown
- 2020-08-31 CA CA3152521A patent/CA3152521A1/en active Pending
- 2020-08-31 HU HUE20771408A patent/HUE067135T2/hu unknown
- 2020-08-31 AU AU2020336984A patent/AU2020336984B2/en active Active
- 2020-08-31 AR ARP200102442A patent/AR119871A1/es unknown
- 2020-08-31 JP JP2022513165A patent/JP2022546042A/ja active Pending
- 2020-08-31 ES ES20771408T patent/ES2987156T3/es active Active
- 2020-08-31 RS RS20240792A patent/RS65763B1/sr unknown
- 2020-08-31 PL PL20771408.0T patent/PL4021575T3/pl unknown
- 2020-08-31 SM SM20240315T patent/SMT202400315T1/it unknown
- 2020-08-31 SI SI202030455T patent/SI4021575T1/sl unknown
- 2020-08-31 PT PT207714080T patent/PT4021575T/pt unknown
- 2020-08-31 DK DK20771408.0T patent/DK4021575T3/da active
- 2020-08-31 BR BR112022003598A patent/BR112022003598A2/pt unknown
- 2020-08-31 HR HRP20220370AA patent/HRP20220370A1/hr not_active Application Discontinuation
-
2022
- 2022-02-21 IL IL290763A patent/IL290763A/en unknown
- 2022-02-28 CL CL2022000496A patent/CL2022000496A1/es unknown
-
2025
- 2025-08-12 JP JP2025134120A patent/JP2025165414A/ja active Pending
-
2026
- 2026-04-07 AU AU2026202611A patent/AU2026202611A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103096918A (zh) * | 2010-06-25 | 2013-05-08 | 夏尔人类遗传性治疗公司 | 治疗试剂的cns 递送 |
| CN107847615A (zh) * | 2015-05-08 | 2018-03-27 | 生物马林药物股份有限公司 | 用于治疗cln2疾病的tpp1调配物及方法 |
Non-Patent Citations (3)
| Title |
|---|
| ALFRIED KOHLSCHÜTTER等: "Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses", 《CNS DRUGS》, vol. 33, no. 4, 1 April 2019 (2019-04-01), pages 315 - 325, XP055694540, DOI: 10.1007/s40263-019-00620-8 * |
| BIOMARIN PHARMACEUTICALS: "ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS", pages 3 - 4, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/product-information/brineura-epar-product-information_en> * |
| BIOMARIN PHARMACUETICALS: "BioMarin Announces Ongoing Study Demonstrates Durable Treatment Benefit from Brineura® (cerliponase alfa) for 3 Years Reduced Rate of Decline Maintained in Children with CLN2 Disease, a Form of Batten Disease", Retrieved from the Internet <URL:http://investors.biomarin.com/2019-02-07-BioMarin-Announces-Ongoing-Study-Demonstrates-Durable-Treatment-Benefit-from-Brineura-R-cerliponase-alfa-for-3-years> * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4021575B1 (en) | 2024-05-22 |
| JP2022546042A (ja) | 2022-11-02 |
| PL4021575T3 (pl) | 2024-09-23 |
| ES2987156T3 (es) | 2024-11-14 |
| HUE067135T2 (hu) | 2024-10-28 |
| MX2022002451A (es) | 2022-06-02 |
| RS65763B1 (sr) | 2024-08-30 |
| KR20220054375A (ko) | 2022-05-02 |
| SMT202400315T1 (it) | 2024-09-16 |
| FI4021575T3 (fi) | 2024-07-24 |
| EP4021575A1 (en) | 2022-07-06 |
| PT4021575T (pt) | 2024-07-30 |
| LT4021575T (lt) | 2024-08-12 |
| AR119871A1 (es) | 2022-01-19 |
| AU2020336984B2 (en) | 2026-04-23 |
| TW202122106A (zh) | 2021-06-16 |
| HRP20240871T1 (hr) | 2024-10-11 |
| US20220273775A1 (en) | 2022-09-01 |
| WO2021042020A1 (en) | 2021-03-04 |
| HRP20220370A1 (hr) | 2022-09-16 |
| CL2022000496A1 (es) | 2022-10-21 |
| JP2025165414A (ja) | 2025-11-04 |
| SI4021575T1 (sl) | 2024-10-30 |
| EP4438120A2 (en) | 2024-10-02 |
| AU2020336984A1 (en) | 2022-03-10 |
| IL290763A (en) | 2022-04-01 |
| AU2026202611A1 (en) | 2026-06-04 |
| CA3152521A1 (en) | 2021-03-04 |
| EP4438120A3 (en) | 2024-12-11 |
| BR112022003598A2 (pt) | 2022-05-24 |
| DK4021575T3 (da) | 2024-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7818561B2 (ja) | デクスメデトミジンを用いて小児患者を治療する方法 | |
| US11229687B2 (en) | TPP-1 formulations and methods for treating CLN2 disease | |
| Hughes et al. | A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease | |
| JP2025165414A (ja) | 小児対象のcln2疾患を治療するための方法 | |
| HK40077860A (en) | Methods for treating cln2 disease in pediatric subjects | |
| RU2848083C1 (ru) | Способы лечения заболевания cln2 у детей | |
| HK40117495A (en) | Methods for treating cln2 disease in pediatric subjects | |
| HK40077045A (en) | Methods for treating cln2 disease in pediatric subjects | |
| HK40077045B (en) | Methods for treating cln2 disease in pediatric subjects | |
| Palabiyik | Biotinidase deficiency | |
| Vrdoljak | Neonatalne konvulzije | |
| Gunawan et al. | Tuberous sclerosis complex in a child: diagnosis and management | |
| HK1250479B (en) | Tpp1 formulations and methods for treating cln2 disease | |
| BR112017023805B1 (pt) | Formulações e composições de tpp1, bem como uso no tratamento de doença lcn2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40077860 Country of ref document: HK |